Small bowel adenocarcinoma (SBA) — a case report by Polczyk, Joanna
137
Case report
NOWOTWORY Journal of Oncology
2017, volume 67, number 2, 137–141 
DOI: 10.5603/NJO.2017.0022 
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X
www.nowotwory.edu.pl
Department of General and Endocrine Surgery, School of Medicine with the Division of Dentistry in Zabrze,  
Medical University of Silesia, Katowice, Poland
Department of General Surgery, Municipal Hospital, Zabrze, Poland
Small bowel adenocarcinoma (SBA) — a case report
Joanna Polczyk
Backround. Small bowel cancers account for less than 0.5% of all malignancies and approximately 1–3% of gas-
trointestinal tract malignancies. The two major tumour types are carcinoid and adenocarcinoma. The latter is most 
commonly found in the duodenum and jejunum, but least often in the ileum.
Case presentation. We present a case study of a 67-year-old woman with small bowel adenocarcinoma (SBA) of the 
ileum. The patient was admitted to the hospital with nonspecific, persistent, recurrent pain in her upper abdomen 
and with suspected subileus. Previously performed clinical investigation (i.e. colonoscopy, computed tomography 
scans — CT scans, small bowel follow-through) didn’t reveal any abnormalities. At laparotomy we discovered a round 
mass obstructing the ileal lumen at about 40 cm from the Bauhin valve. A tumour was then resected within its surgi-
cal margins. Pathologic examination revealed an ileal adenocarcinoma and an infiltration of the local adipose tissue 
(Adenocarcinoma G3 partim gelatinosum), with no evidence of metastatic lesions in the lymph nodes nor into other 
organs (pT3N0M0; the clinical stage IIA). Further oncological treatment was thereby advised. 
Conclusions. A low prevalence and non-specific symptoms along without any clearly established diagnostic nor 
treatment protocols makes a final diagnosis difficult and thus merits further diagnostic investigation, particularly 
the testing of specific biochemical or immunological markers.
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Introduction
The small bowel comprises 75% of intestinal length and 
90% of the gastrointestinal tract surface [1]. Small bowel ma-
lignancies account for less than 0.5% of all the malignancies 
and about 1–3% gastrointestinal tract malignancies [2]. In 
2013, small bowel malignancies had been diagnosed in 126 
polish women and 134 polish men [3]. The most common 
histological types of small bowel cancer are adenocarci-
noma and carcinoid tumour. The others include lympho-
ma, sarcoma and gastrointestinal stromal tumours (GIST) 
(Tab. I), [2]. Small bowel adenocarcinoma (SBA) is most com-
monly located in the duodenum (57%) and jejunum (29%), 
whereas it is most rarely found in the ileum (10%) [1, 4, 5], 
while carcinoid tumour and sarcoma are most commonly 
found in the ileum [1, 2, 6].
The risk factors for SBA include: familial adenomatous 
polyposis (FAP), Lynch II syndrome (HNPCC, hereditary non-
-polyposis colorectal cancer), Peutz-Jeghers syndrome, spo-
radic polyps, Crohn’s disease, coeliac disease, AIDS, a history 
of cholecystectomy, smoking and alcohol consumption 
[1, 2, 5, 7]. The median age at diagnosis for SBA is 67 years 
with over 85% of patients presenting after age 50 [1]. Clini-
cal presentation of SBA is asymptomatic in the long term, 
which leads to diagnosis being delayed by an average of 
about 6 months [4]. When symptoms successively develop, 
they present as nonspecific abdominal discomfort and/or: 
weight loss, anaemia, gastrointestinal bleeding, diarrhea 
and postprandial abdominal pain. Ultimately, at locally ad-
vanced stages, the patient is admitted to hospital with so 
called ‘acute abdomen’ symptoms [1, 2, 5, 8].
Standard available diagnostic procedures like abdomi-
nal ultrasound, oesophagogastroduodenal endoscopy and 
colonoscopy enable the diagnosis of only those tumours 
localised in duodenum, whereas abdominal computed to-
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mography scans (CT scans) do not usually visualize any 
abdominal mass but only visualize nonspecific changes in 
the small bowel like swollen lymph nodes or thickening of 
the bowel wall. Without any principal diagnosis, with only 
a suspicion of lesions in the distal segment of small bowel, this 
then prompts the use of more advanced methods: endoscopy 
(video capsule endoscopy, double-balloon assisted enteros-
copy), imaging techniques using computed tomography (CT) 
and magnetic resonance; CT/MRI enteroclysis and CT/MRI 
enterography. Furthermore, arteriography, scintigraphy and 
small bowel follow-through are increasingly becoming more 
important for evaluating small bowel disease [1, 2, 5, 7, 8]. 
Despite the wide spectrum these aforementioned diagnostic 
methods we are still missing a specific screening method 
that could simultaneously meet the following criteria: cost, 
availability, precision of intestinal lumen evaluation together 
being able to take samples for pathological examination, 
and invasiveness. Despite these aforementioned procedures 
being all performed in Poland, they are unfortunately only 
readily available usually at highly specialized medical centres. 
Case presentation
A 67-year old female patient, 6 months after a previously 
performed laparoscopic cholecystectomy due to cholecys-
tolithiasis was re-admitted to the Department of General 
Surgery at the Zabrze Municipal Hospital suspected with 
an incomplete small bowel obstruction. She had a medical 
history of hypothyroidism, chronic obturative pulmonary 
disease, type 2 diabetes mellitus, hypertension and colonic 
diverticular disease. 
For about the last 6 months, the patient experienced 
recurrent epigastric colicky pain and abdominal distention. 
After one of the first episodes, the patient underwent a full 
diagnostic procedure in the aforementioned Department of 
General Surgery, which did not reveal any abnormalities. An 
oesophagogastroduodenal endoscopy performed at that 
time demonstrated bile reflux erosive gastritis. In a colo-
noscopy, hyperplastic polyps were simultaneously excised 
in the caecum, near the orifice of the vermiform appendix, 
transverse colon, sigmoid colon and rectum. Small bowel 
follow-through with gastrografin also did not reveal any 
abnormalities (Fig. 1). CT scans of the abdomen and pelvis 
demonstrated an intestine without increased fluid levels, 
but with only a segmental jejunal dilatation up to about 
29 mm accompanied with a segmental ileal wall thickening 
of up to about 11–13 mm diameter suggesting the presence 
of an inflammatory process. No swollen lymph nodes in the 
abdomen nor pelvis were found (Fig. 2). Laboratory tests 
were unremarkable except for slightly elevated inflamma-
tion parameters (Tab. II).
The constant upper abdominal pain was suspected to 
result from post-cholecystectomy syndrome of the bile 
reflux gastritis. The reason why the patient attended our 
Department was that this abdominal pain was continuously 
lasting for several days. She experienced vomiting several 
times daily before and on admission. She was passing gas 
regularly and the last defecation had occurred a week before 
admission to the Department.
Physical examination on admission revealed a soft ab-
domen with tenderness in the upper middle quadrant. No 
pathological mass was palpated in the abdomen. Peristalsis 
was present, with no metallic tinkling, and digital rectal 
examination showed the rectal ampulla full of brown stool. 
Plain abdominal radiography demonstrated intestines with 
increased fluid levels in the left abdomen; there being no 
free gas within the peritoneal cavity (Fig. 3).
Due to patient’s state deteriorating and aggravated ab-
dominal pain, a decision for emergency surgery was made. 
The abdomen was opened with a midline incision centreing 
the umbilicus. There was a small amount of serous fluid in the 
abdominal cavity which was collected for microbiology inves-
tigation. The small intestine was dilated with a thickened and 
overworked wall extending almost the whole length up to the 
obstacle. About 40 cm from the Bauhin valve a tumour was 
found to occlude the bowel lumen and was invading directly 
into the neighbouring mesentery. A radical resection of the 
pathologically changed ileum segment and the entire tumour 
along with its mesenteric involvement was performed and the 
specimen sent for pathologic investigation. Gastrointestinal 
tract anastomosis was performed by a side-to-side ileo-ileal 
anastomosis technique with double-layer continuous sutures. 
The mesentery of the small intestine was closed with inter-
rupted sutures to prevent internal hernia. After controlling 
the bleeding, the abdominal cavity was flushed with a warm 
saline solution. The abdomen was then closed in layers and 
sterile dressing applied to the wound.
The pathological examination of the resected specimen 
demonstrated ileal adenocarcinoma (G3 partim gelatino-
sum) infiltrating local adipose tissue, with all the lymph 
nodes being negative and no metastases to other organs 
(pT3N0M0; the clinical stage IIA). The level of carcino-em-
bryonic antigen (CEA) was normal (< 5 mg/mL).
The postoperative period was uncomplicated and the 
patient was discharged on the 12th postoperative day in 
Table I. Incidence of the most common pathological types of small bowel malignancies [2, 4]
Pathological type of small bowel malignancies Carcinoid Adenocarcinoma Lymphoma Sarcoma GEP-NET GIST
The incidence in % 35–42 30–40 15–20 10–15 20–50 7
GIST — gastrointestinal stromal tumour; GEP-NET — gastroenteropancreatic neuroendocrine tumours
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a satisfactory condition for further systemic treatment at 
the Department of Radiotherapy and Chemiotherapy in 
the Centre of Oncology, Maria Skłodowska-Curie Memorial 
Institute, Gliwice Branch, where she is continuing a fifth cycle 
of LF1 (5-Fluorouracil+Sodium Levofolinate).
Discussion
Our case study has shown that an early and accurate 
diagnosis of small bowel malignancies is still difficult to 
achieve and is often only possible intraoperatively. Recent 
improvements in advanced diagnostic imaging methods 
and developments to video capsule endoscopy has im-
proved the numbers of correct diagnoses made of small 
bowel malignancies, however this procedure is still barely 
available in Poland [8]. The lack of there being any unambig-
uous biochemical or immunological markers together with 
nonspecific symptoms often delays diagnosis, consequently 
prolonging the time for delivering adequate oncological 
treatment. It thus appears necessary to seek for new, easy, 
highly sensitive and highly specific markers of SBA. 
Figure 1. Small bowel follow-through with gastrografin. A sequence of images visualizing the contrast reaching towards the end of the small intestine
Figure 2. Abdominal and pelvic CT scans with contrast. We observe 
segmental wall thickening of the ileal loop
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The most effective method for treatment is a radical sur-
gical resection of the intestine within surgical margins and 
regional lymph node assessment (minimum 8) [1, 2, 4, 5, 8, 9]. 
Prognosis depends on locoregional disease and the tumour 
resectability stage. Poor prognosis factors include: duodenal 
location, male gender, black ethnicity, older age, poor differen-
tiation, positive margins and lymph node invasion [1]. Systemic 
treatment in metastatic SBA is based on adjuvant chemothera-
py with the combination of fluoropyrimidine (i.e. 5-fluorouracyl 
or capecytabine) and oxaliplatin as supported by promising 
outcomes found recently in a few retrospective clinical stu- 
dies [1, 10]. It transpires that the protocol used for treating colo-
rectal adenocarcinoma has shown a survival benefit for SBA 
patients. Of the four prospective clinical trials reported, three 
studies combining fluoropyrimidine with oxaliplatin have 
shown similar performance with response rates (RR) of 42% to 
50% and a median time to progression (TTP), ranging from 7.8 to 
9.8 months [1, 11–13].
Despite the small bowel possessing the greatest absorp-
tion surface area of the alimentary tract, SBA has a 50-fold 
lower incidence than large bowel adenocarcinoma. There 
are several hypotheses proposed to explain the apparent 
resistance of the small intestine to carcinogenesis. It is be-
lieved, that rapid turnover of small intestine epithelium 
eliminates the accumulation of genetic damage and the 
increased lymphoid tissue of the small intestine provides 
increased mucosal immune surveillance. Due to rapid tran-
sit time of digesta, the concentration of aerophilic Gram-
positive bacteria increases in the distal ileum and a dilute 
alkaline environment and lack of bacterial degradation 
activity decrease the exposure to dietary carcinogens [1, 5]. 
Unfortunately, SBA has a worse prognosis and treatment 
outcomes compared to colorectal adenocarcinoma. Because 
access is difficult for any impeding examination as well as the 
insidious course of the disease, the non-specific symptoms 
and low prevalence, these factors contribute to there being 
32% of patients with SBA seen at the disease stage IV at the 
time of diagnosis. Duodenal SBA appears to have a worse 
prognosis than jejunal or ileal SBA but the reason is unex-
plained. It may be assumed that incomplete lymph node 
resection at surgery and misclassifying some patients suffer-
ing from adenocarcinoma of the ampulla of Vater as having 
duodenal SBA could explain this finding; ampullary cancer 
should be treated with gemcitabine-based regimens [10, 14].
A number of ongoing clinical trials are focused on ex-
ploring molecular similarities between SBA and colorectal 
adenocarcinoma in order to find alternative therapeutic 
methods. A new chance for treatment is provided by target-
ed therapy using human monoclonal antibodies (cetuximab, 
bewacizumab), that possess high affinity and specificity for 
the epidermal growth factor receptor (EGFR). A handful of 
case reports have also described responses to anti-EGFR the-
rapy in SBA patients with KRAS wild-type tumours [1, 5, 15]. 
The SBA treatment protocol is nevertheless still vague, main-
ly due to the low prevalence of SBA and too few prospective 
clinical trials [10].
Figure 3. Plain radiograph of the abdomen shows multiple air-fluid 
levels
Table II. Laboratory tests results during hospitalization
Date/Lab.test CRP 
[mg/L]
WBC 
[thou./µL]
RBC 
[mill./ µL]
Hgb 
[g/dL]
PLT 
[thou./µL]
Creatinine 
[mg/dl]
Potassium 
[mmol/l]
18.04 7.39 12  4.2 15  340 0.92  3.9
22.04 13.32 15 4.65 13.8 397 0.74 4
26.04 10.31 10.9 4.06 12.9 352 0.89 4.51
11.05 44 10 4.51 13.5 374 1.47 5.23
17.05  20 10.7 3.99 11.9 371 0.9 3.74
8.06 4.42 12.1 5.3 15.3 437 1.39 4.22
WBC — white blood cell count; RBC — red blood cell count; PLT — platelets; CRP — C reactive protein; Hgb — hemoglobin
141
Conclusions
Given the rarity of this cancer and a lack of a representa-
tive group of SBA patients, we are still far from creating an 
optimal method for diagnostics and treatment.
Examination of rare tumours is a great scientific chal-
lenge and it demands multicentered clinical trials and close 
collaboration between medical doctors and a wide group 
of scientists. Elucidating precisely the molecular biology of 
SBA may not only improve our oncological vigilance, but 
also contribute to discovery of novel therapeutic agents for 
those patients specifically at high risk of SBA (i.e. patients 
with coeliac disease, Crohn’s disease and Lynch II syndrome). 
All treatment decisions should be made on a multidiscipli-
nary basis. Such a group should consist of: an oncological 
surgeon, clinical oncologist, radiotherapeutist, and special-
ists in radiology and pathomorphology.
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